PRA Voted "Best CRO" In Asia
RALEIGH, N.C., March 25, 2013 /PRNewswire/ -- PRA, a leading clinical research organization, today announced it was voted "Best CRO" for the 3 rd annual BioPharma Asia Industry Awards 2013. The winner was announced March 19 at an awards dinner in Singapore.
"We are deeply honored to have been voted 'Best CRO'," said Kent Thoelke, PRA executive vice president, Scientific and Medical Affairs. "We have been working hard to continually meet the growing needs of our clients in this region, and I'm confident that we will continue to enhance our capability in the Asia Pacific region while ensuring we provide high-quality services."
"PRA has been strategically expanding its operations and has achieved several key expansion milestones in Asia Pacific," said Helen Neal, PRA director, Clinical Operations Asia Pacific. "We recently formed a joint venture with Wuxi PharmaTech in China, opened offices in Singapore, and expanded operations in South Korea."
Organized by Terrapinn, the awards honor and generate public recognition of the efforts, accomplishments and positive contributions of organizations and individuals in Asia's biopharmaceutical industry. They identify and reward those who demonstrate an ability to succeed, continually set standards of excellence, and who will be the future of the biopharmaceutical industry.There are nine award categories: Best LSP Award; Best Contract Research Organization Award; Best Contract Manufacturing Organization Award; Most Innovative Asian Biotech Award; Asian Executive of the Year; Woman Executive of the Year; Best Manufacturing Solution Provider Award; Best Drug Pipeline Award; and Pharma Company of the Year.
About PRA PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV